Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: The role of anthracycline dose intensity

Cecilia Bozzetti, Antonino Musolino, Roberta Camisa, Giancarlo Bisagni, Marcella Flora, Cristina Bassano, Eugenia Martella, Costanza Lagrasta, Rita Nizzoli, Nicola Personeni, Francesco Leonardi, Giorgio Cocconi, Andrea Ardizzoni

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: The value of HER-2/neu status as a predictor of response to anthracycline-based chemotherapy is still a matter of debate. We evaluated the contribution of HER-2/neu gene amplification and other biologic markers in predicting response to different doses of neoadjuvant anthracycline-based chemotherapy. METHODS: Clinical and pathologic records of 115 primary breast cancer patients were reviewed. Forty-eight and 67 patients received high (doxorubicin ≥20 mg/m/wk; epirubicin ≥30 mg/m/wk) and moderate-low anthracycline dose intensity regimens, respectively. Pathologic diagnosis, hormonal receptor status (HR), Ki67, and HER-2/neu status were assessed on tumor samples before neoadjuvant chemotherapy. HER-2/neu was determined by fluorescence in situ hybridization (FISH). RESULTS: HER-2/neu amplification was observed in 29/115 (25%) tumors, 18 from moderate-low-dose and 11 from high-dose group. In the univariate analysis, a high Ki67 index (≥20%) and positive clinical axillary nodes were predictive of an objective tumor response (P = 0.033 and 0.001, respectively). In the multivariate analysis, Ki67 was the only factor predictive of response (OR = 3.08, 95% CI = 1.1-8.5, P = 0.03). HER-2/neu status was not a factor in predicting objective response to different anthracycline dose intensities. The same finding was observed with regards to HR and Ki67. CONCLUSIONS: In our series, no significant dose-response relationship was found according to HER-2/neu status.

Original languageEnglish
Pages (from-to)171-177
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume29
Issue number2
DOIs
Publication statusPublished - Apr 2006

Keywords

  • Anthracyclines
  • Breast cancer
  • HER-2/neu
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: The role of anthracycline dose intensity'. Together they form a unique fingerprint.

Cite this